We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Rapid Genetic Test Developed for an Often Fatal Mitochondrial Disease

By LabMedica International staff writers
Posted on 19 Jul 2016
Print article
Image: Mitochondria. Researchers have inherited mutations in the TMEM126B gene that cause debilitating and often fatal disease from infancy, and have developed a rapid diagnostic test that has already identified 6 patients from 4 families (Image courtesy of Newcastle University).
Image: Mitochondria. Researchers have inherited mutations in the TMEM126B gene that cause debilitating and often fatal disease from infancy, and have developed a rapid diagnostic test that has already identified 6 patients from 4 families (Image courtesy of Newcastle University).
Researchers have discovered disease-causing inherited mutations in the TMEM126B gene and developed a test providing rapid diagnosis of related mitochondrial disorders. Defects in TMEM126B cause problems with energy generation in muscles, and can lead to muscular weakness, blindness, fatal heart failure, liver failure, learning disability, diabetes, and seizures. There is currently no cure and affected children often die in early infancy.

A team of medics and scientists at Wellcome Trust Centre for Mitochondrial Research, Newcastle University (Newcastle, Tyne & Wear, UK), together with international collaborators identified the mutations and used next generation sequencing (NGS) to develop the test, which provides a result within 2-3 days. Their research confirmed the identity of a mutation in TMEM126B that causes mitochondrial disease affecting Complex I, one of five complexes involved in energy production. TMEM126B normally makes a protein necessary for complex I assembly.

First author Charlotte Alston, PhD student, described the technique, which has already identified 6 patients from 4 families affected by this form of mitochondrial disease: “Identifying a fault in Complex I [...] combined with our custom gene capture and the latest sequencing technology means we can screen many more genes to diagnose this debilitating disease. It means families can get a rapid diagnosis within days rather than the weeks and months that testing can currently take. For families who are waiting on a genetic diagnosis before trying for another baby, or they may already be expecting their next child, time really is of the essence.”

Senior author Professor Rob Taylor said: “The diagnosis of mitochondrial disease is often a complicated and time consuming process. There are over 1,300 potential genes that can lead to disease and, as such, finding the genetic cause is sometimes like looking for a needle in a haystack.”

For a family with one child affected with this type of mitochondrial disease, there is a 25% chance of each further child being affected. Professor Taylor added: “There is sadly no cure for mitochondrial disease so rapid diagnosis means parents who are wanting to have further children can opt for prenatal testing to ensure future children are healthy and without risk of developing severe disease. It provides options for families at risk of an otherwise incurable disease.”

The study, by Alston CL et al, was published July 7, 2016, in the American Journal of Human Genetics.

Related Links:
Newcastle University
Wellcome Trust Centre for Mitochondrial Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.